Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report.
Elemento
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicaciónTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Título
Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report.
Materia
Descripción
The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients.
Fecha
2020-05-02
Tipo
Citación
Hammami, Muhammad Baraa, Brian Garibaldi, Pali Shah, Gigi Liu, Tania Jain, Po-Hung Chen, Amy K. Kim, Edina Avdic, Brent Petty, Sara Strout, Derek M. Fine, Ashwini Niranjan-Azadi, William M. Garneau, Andrew M. Cameron, Jose M. Monroy Trujillo, Ahmet Gurakar, and Robin Avery. 2020. "Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report." American Journal of Transplantation n/a (n/a).
Resumen
The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. We report the clinical course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory manifestations with rapid improvement after administration of off-label, single-dose tocilizumab. We also highlight the role of lung ultrasonography in early diagnosis of the inflammatory phase of COVID-19. Future investigation of the effects of immunomodulators among transplant recipients with COVID-19 infection will be important.
This article is protected by copyright. All rights reserved.
Accesibilidad
Free online
Was this resource helpful?